FULC vs. NGNE, LRMR, KRRO, ALT, TVTX, ANRO, ANNX, SLRN, TBPH, and KALV
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Neurogene (NGNE), Larimar Therapeutics (LRMR), Korro Bio (KRRO), Altimmune (ALT), Travere Therapeutics (TVTX), Alto Neuroscience (ANRO), Annexon (ANNX), Acelyrin (SLRN), Theravance Biopharma (TBPH), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical preparations" industry.
Neurogene (NASDAQ:NGNE) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
Neurogene has a net margin of 0.00% compared to Neurogene's net margin of -3,470.05%. Fulcrum Therapeutics' return on equity of -31.17% beat Neurogene's return on equity.
52.4% of Neurogene shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 1.6% of Neurogene shares are owned by insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Neurogene has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.
In the previous week, Neurogene had 8 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 12 mentions for Neurogene and 4 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.69 beat Neurogene's score of 0.45 indicating that Neurogene is being referred to more favorably in the media.
Fulcrum Therapeutics received 82 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 63.89% of users gave Fulcrum Therapeutics an outperform vote.
Neurogene currently has a consensus price target of $48.25, indicating a potential upside of 46.66%. Fulcrum Therapeutics has a consensus price target of $13.17, indicating a potential upside of 73.47%. Given Neurogene's higher probable upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Neurogene.
Neurogene has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500.
Summary
Neurogene beats Fulcrum Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
